Micafungin Xellia (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. This disruption weakens the cell wall, leading to osmotic instability and cell death, while human cells are unaffected because they lack this pathway.

The specific dose and infusion schedule of Micafungin Xellia are determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare providers set the appropriate regimen for each individual case.

The safety of Micafungin Xellia in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Micafungin Xellia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins, including micafungin, are generally well‑tolerated and have fewer drug‑drug interactions, making them a preferred option for invasive Candida infections, especially in patients receiving multiple concomitant medications.

Micafungin Xellia should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability and potency.

Micafungin Xellia is given as an intravenous infusion. The infusion is typically administered over a period of 30‑60 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy.

Serious risks include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and rare cases of renal impairment. Patients should be monitored for signs of liver dysfunction, allergic responses, and changes in kidney function throughout treatment.

Micafungin Xellia is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, as the drug may exacerbate hepatic injury.